In conclusion, by investigating a multi-centric cohort of MS patients treated with NTZ, we were able to highlight a variant with a putative role in response to drug, rs11132400, and two genes already implicated in MS pathogenesis, GRB2 and LRP6. In addition, from the network module perspective, we report an enrichment of Wnt/β-catenin signaling pathway, which is an essential component for BBB formation and maintenance. The gene discussed is LRP6; the disease is myeloid sarcoma.